Shanghai Haoyuan Chemexpress Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Shanghai Haoyuan Chemexpress's earnings have been declining at an average annual rate of -1.2%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 29.9% per year. Shanghai Haoyuan Chemexpress's return on equity is 5.5%, and it has net margins of 7.2%.
Belangrijke informatie
-1.2%
Groei van de winst
-8.9%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 26.8% |
| Inkomstengroei | 29.9% |
| Rendement op eigen vermogen | 5.5% |
| Nettomarge | 7.2% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Does Shanghai Haoyuan Chemexpress (SHSE:688131) Have A Healthy Balance Sheet?
Oct 16
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) 25% Jump Shows Its Popularity With Investors
Sep 19Investors Appear Satisfied With Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Prospects
Jul 13Shanghai Haoyuan Chemexpress (SHSE:688131) Has A Somewhat Strained Balance Sheet
Jun 13Earnings Troubles May Signal Larger Issues for Shanghai Haoyuan Chemexpress (SHSE:688131) Shareholders
May 06After Leaping 27% Shanghai Haoyuan Chemexpress Co., Ltd. (SHSE:688131) Shares Are Not Flying Under The Radar
Mar 20Opbrengsten en kosten
Hoe Shanghai Haoyuan Chemexpress geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 2,123 | 153 | 426 | 225 |
| 30 Jun 24 | 2,055 | 103 | 424 | 228 |
| 31 Mar 24 | 1,967 | 98 | 404 | 227 |
| 31 Dec 23 | 1,880 | 127 | 389 | 224 |
| 30 Sep 23 | 1,764 | 154 | 384 | 232 |
| 30 Jun 23 | 1,618 | 172 | 350 | 227 |
| 31 Mar 23 | 1,476 | 178 | 319 | 219 |
| 31 Dec 22 | 1,358 | 194 | 290 | 202 |
| 30 Sep 22 | 1,243 | 205 | 259 | 176 |
| 30 Jun 22 | 1,135 | 212 | 235 | 143 |
| 31 Mar 22 | 1,044 | 199 | 217 | 119 |
| 31 Dec 21 | 969 | 191 | 188 | 103 |
| 30 Sep 21 | 918 | 202 | 151 | 87 |
| 30 Jun 21 | 841 | 178 | 141 | 79 |
| 31 Mar 21 | 736 | 160 | 121 | 69 |
| 31 Dec 20 | 635 | 128 | 117 | 65 |
| 31 Dec 19 | 409 | 73 | 90 | 53 |
| 31 Dec 18 | 300 | 18 | 88 | 35 |
| 30 Jun 17 | 150 | 31 | 46 | 0 |
| 31 Mar 17 | 134 | 24 | 41 | 0 |
| 31 Dec 16 | 117 | 18 | 37 | 0 |
| 30 Sep 16 | 116 | 18 | 33 | 0 |
| 30 Jun 16 | 96 | 11 | 24 | 0 |
| 31 Mar 16 | 94 | 10 | 22 | 0 |
| 31 Dec 15 | 92 | 9 | 20 | 0 |
| 31 Dec 14 | 67 | 3 | 15 | 0 |
| 31 Dec 13 | 59 | 2 | 12 | 0 |
Kwaliteitswinsten: 688131 has high quality earnings.
Groeiende winstmarge: 688131's current net profit margins (7.2%) are lower than last year (8.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 688131's earnings have declined by 1.2% per year over the past 5 years.
Versnelling van de groei: 688131's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 688131 had negative earnings growth (-0.9%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).
Rendement op eigen vermogen
Hoge ROE: 688131's Return on Equity (5.5%) is considered low.